Regenerative Medicine Expo TOKYO Conference


Industry leaders address regenerative medicine technologies. CAR-T Cell Therapy, iPS Cells for Disease Modeling and Drug Discovery, etc. will be discussed.

>>> Sessions listed here are all bilingual session with English & Japanese.
For the full program, please visit
https://www.regenmed-t.jp/seminar/
(available only in Japanese)

Supervisor

Yuzo Toda Former Chairman, Forum for Innovative Regenerative Medicine(FIRM)

Keynote Session Pre-registration Required

Application reopened on June 26.

RM-K
July 4 (Thu) 13:00  -  14:30

Future Medical Care & Drug Development with Regenerative Medicine

  • English / Japanese

Development of Chimeric Antigen Receptor T-cell Treatment in Novartis

Tohru Hirose Director, Div.Head, Japan Development, Novartis Pharma K.K.

Detail & Speaker’s Profile

<Detail>
The development of Chimeric Antigen Receptor T-cell (CAR-T) treatment, CTL019: tisagenlecleucel, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor for the patients with relapsed or refractory CD19 positive Acute Lymphoblastic Leukemia and Diffused Large B Cell Lymphoma.

<Speaker’s Profile>

iPSCs-based Regenerative Medicine and Drug Development

Hideyuki Okano Dean, Keio University Graduate School of Medicine/ Professor, Dept. of Physiology, Keio University School of Medicine

Detail & Speaker’s Profile

<Detail>
There is increasing interest in regenerative medicine and drug development as medical application of iPSCs-technology. Here, I will talk about clinical trials of our iPSCs-based cell therapy for spinal cord injury and patients-based drug development for ALS.

<Speaker’s Profile>
Hideyuki Okano received M.D. in Physiology from Keio University in 1983. He held post doctoral position in Johns Hopkins University School of Medicine. He was appointed full professors at Keio University Medical School in 2001 as a full professor of Physiology.


Exhibitors' Presentation Free / No Registration Required

Exhibitors will give presentations about the latest products/technologies.

>> Program

No registration required.
Please go to the venue (inside exhibition hall) directly.
Please note that some presentations might be given only in Japanese.

Concurrent Conferences Pre-registration Required

IPJ-K July 3 (Wed) 10:30  -  11:30

Japanese Pharmaceutical Industry -- What is the Key to Growth?

  • English / Japanese
Course Leader Hirofumi Takeuchi, Professor, Gifu Pharmaceutical University

The Astellas Vision for the Future of Healthcare

Yoshihiko Hatanaka Representative Director, Chairman of the Board, Astellas Pharma Inc.

Detail & Speaker’s Profile

<Detail>
Healthcare needs are drastically changing with economic and social structure transition due to aging.
Astellas strives to create medical solutions that provide value to society through new modality / technology and digital transformation, including cell therapy and digital health programs.

<Speaker’s Profile>
Yoshihiko Hatanaka
Representative Director, Chairman of the Board
Astellas Pharma Inc.

Yoshihiko Hatanaka became Astellas' Chairman of the Board in April 2018. Hatanaka served as the company's President and CEO from June 2011 to March 2018.
He joined the marketing organization of Fujisawa Pharmaceutical Co., Ltd. in 1980 and expanded his roles and responsibilities in Japan, the US and Europe. He became Fujisawa's Vice President of the Corporate Planning in 2003 and played a key role in the merger of Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. to form Astellas Pharma Inc. in 2005. He kept the senior level position under the new company. He assumed the roles of President and CEO of Astellas US LLC and Astellas Pharma US, Inc. in 2006, and Chief Financial Officer and Chief Strategy Officer of Astellas Pharma Inc. in 2009. He holds a bachelor's degree in Economics from Hitotsubashi Univercity, Tokyo, Japan

* Please note that the session is rescheduled to 13:00 – 14:30. [May 22, 2019]

BP-K
July 3 (Wed) 13:00  -  14:30

Japanese Biopharmaceutical Industry's Steps for Growth -- Japanese Companies' Challenges and Future Perspective

  • English / Japanese

Evolution of Biotechnology and Creation of Innovation in Medicine

Hisafumi Okabe Executive Vice President, Research, Translational Research, General Manager of Translational Research Div., Chugai Pharmaceutical Co., Ltd.

Detail & Speaker’s Profile

<Detail>
Recent progress in biotechnologies has brought rapid evolution of existing biologics as well as development of new modalities. In this session, I will talk about the evolution of therapeutic antibodies and emerging new modalities, and also touch on industry-academia collaboration to accelerate the innovation.

<Speaker’s Profile>
Education: Institute of Medical Science, The University of Tokyo, Faculty of Science, Tohoku University(Ph.D.).
Professional career: Researcher at Metropolitan Institute of Medical Science, Postdoc at Yale University, Researcher at Nippon Roche Research Center, Executive Vice President, Head of Research and Translational Research at Chugai Pharmaceutical Co., Ltd.

AGC's Challenge to Raise Japan's Competitiveness in Biopharmaceuticals

Hideyuki Kurata GM of Technology General Div., Senior Executive Officer, AGC Inc.

Detail & Speaker’s Profile

<Detail>
AGC's brand statement, "Your Dreams, Our Challenge" stands for our determination to bring to life the dreams that lay beyond everyone's thoughts, building a reliable partnership with our customers.
This session will introduce the role and mission of CDMOs in the biopharmaceutical industry in Japan, and AGC's past and present commitments.

<Speaker’s Profile>
 

BP-S2 July 4 (Thu) 10:30  -  12:00
  • FREE / Pre-registration Required

New Nucleic Acid-based Drugs : Drug Discovery & Clinical Application

  • English / Japanese
Course Leader Hisafumi Okabe, Executive Vice President, In charge of Translational Research and General Manager of Translational Research Div., Chugai Pharmaceutical Co., Ltd.

Clinical Application of Nucleic Acid Therapy

Masahiko Kuroda Professor and Chair, Dept. of Molecular Pathology, Tokyo Medical University

Detail & Speaker’s Profile

<Detail>
Nucleic acid therapy are highly attracting great attention. It is highly safe, inexpensive and mass producible, and it is also an attractive tool from the viewpoint of medical economics. In this presentation, I would like to outline the current state of nucleic acid drug development from both the basic and clinical aspects.

<Speaker’s Profile>

RNA as a Target

Mads Aaboe Jensen External Innovation Officer, RNA Molecule Research, Roche Pharma Research & Early Development, Roche Innovation Center Copenhagen A/S

Detail & Speaker’s Profile

<Detail>
RNA molecules are essential for cellular information transfer as they encode proteins and regulate gene expression. Numerous RNAs have been implicated in human diseases. Targeting these RNAs with either oligonucleotides or small molecules provides an opportunity to therapeutically modulate numerous cellular processes.

<Speaker’s Profile>
Mads holds a position as External Innovation Officer at Roche Innovation Center Copenhagen, where he is responsible for scouting and assessment of external opportunities related to nucleic acid based therapies. Prior to this, he was leading a RNA research team with activities in the field of early drug discovery and external innovation. Over the course of his career, Mads has led over 7 RNA therapeutic discovery projects and numerous technology innovation projects which have yielded over 10 patents and patent applications.

PRD-K July 3 (Wed) 10:30  -  12:00

For Innovative Drug R&D

  • English / Japanese

Mission of AMED: Global Data Sharing

Makoto Suematsu President, Japan Agency for Medical Research and Development

Detail & Speaker’s Profile

<Detail>
AMED has chosen a field of rare and undiagnosed diseases to tackle with a number of obstacles including "Balkanization" of mindsets among researchers. Solving Balkanization gives a clue to fast-track implementation of outcomes among all other fields of medical researches. I would present an overview of our missions and visions.

<Speaker’s Profile>

Creating an Innovation Hotspot in Life Science in Japan

Toshio Fujimoto General Manager, Shonan Health Innovation Park, Takeda Pharmaceutical Co., Ltd.

Detail & Speaker’s Profile

<Detail>
Takeda Pharmaceuticals opened a state-of-the-art research facility in Shonan, as a center of open innovation in April, 2018. The new research park aims to create an ecosystem in which researchers with diverse backgrounds will translate cutting-edge science into innovative solutions for the benefit of patients.

<Speaker’s Profile>
not required

PRD-S4 July 5 (Fri) 14:30  -  16:25
  • FREE / Pre-registration Required

Gene Therapy -- Challenges for Next-generation Drug Discovery

  • English / Japanese

Gene Therapy -- Expectation and Reality

Mitsuru Miyata Executive Leader Writer, Nikkei Business Publications, Inc. / President, Miyata Institute of Technologies, MIT

Detail & Speaker’s Profile

<Detail>
A great progress has been made in commercialization of gene therapies. "Zolgensma" by Novartis from Switzerland was approved in US and is expected to be the world's first blockbuster for gene therapy. "Zolgensma" is now being reviewed in Japan as well. There is no doubt that gene therapies will make a huge impact in our country in a near future. Here, we discuss the requirements for gene therapy to be a pillar of the pharmaceutical industry's profits and its pitfalls.

<Speaker’s Profile>
 

Gene Therapy for Neuropathic Pain: Clinical and Commercial Implications

Sunyoung Kim CEO, Helixmith Co., Ltd. (formerly: ViroMed Co., Ltd.)

Detail & Speaker’s Profile

<Detail>
The world's first Phase III clinical study, using plasmid gene therapy, for treating severe neuropathic pain is nearing completion in the USA. I will discuss the scientific rationale and early clinical results with VM202, and if available, either topline results or blinded efficacy and safety from our Phase III study.

<Speaker’s Profile>
- Sunyoung Kim, DPhil, founder and current CEO of Helixmith Co., Ltd.
- Highly regarded as a successful entrepreneurial scientist, Dr. Kim served on the Seoul National University faculty (1992-2018) after serving as an assistant professor at Harvard Medical School (1990-1992).
- Helixmith today is the global leader in the area of plasmid DNA-based gene therapy with focus on neurological and cardiovascular diseases.

Development and Commercialization of Gene Therapy: Focusing on CAR-T Cell Therapy

Keiya Ozawa Professor Emeritus and Visiting Professor of the Div. of Immuno-Gene & Cell Therapy (Takara Bio), School of Medicine, Jichi Medical University

Detail & Speaker’s Profile

<Detail>
Gene therapy has revived. Hematopoietic stem cell gene therapy became safer. AAV vector gene therapy is effective in neurological diseases, eye diseases, and hemophilia. As for cancer gene therapy, development of CAR-T/TCR-T cell therapy is remarkable. Application of genome editing technology is also rapidly progressing.

<Speaker’s Profile>
Keiya Ozawa received his M.D. from University of Tokyo in 1977 and his Ph.D. from University of Tokyo in 1984. He studied at NIH, USA as a Fogarty Fellow (1985-87). In 1994 he became Professor of Jichi Medical School. In 2014 he became Hospital Director of The Institute of Medical Science, The University of Tokyo (IMSUT) and Professor of the Division of Genetic Therapeutics, The Advanced Clinical Research Center, IMSUT. In 2018, he became Professor Emeritus and Visiting Professor of the Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University.

<Concurrent Conference>